Products
Varisacumab Biosimilar Monoclonal Antibody (VEGF-A) for Research
Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Varisacumab (GNR 011), a biosimilar of bevacizumab [see Adis Insight Drug profile 800008086] is under development with International Biotech Center Generium (IBC Generium), for the treatment of various types of cancer, including colorectal, non-small cell lung, glioblastoma and breast cancer, and ophthalmic conditions.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-613-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody |
| INN Name | Varisacumab |
| Target | VEGFA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS |
| Conditions Approved | na |
| Conditions Active | Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer |
| Conditions Discontinued | na |
| Development Tech | na |
About target - VEGFA
1. Protein Vascular endothelial growth factor A
2. Gene VEGFA
3. Organism Homo sapiens (Human)
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).
